A Phase 3 interventional study of DOR/ISL and BIC/FTC/TAF in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and to evaluate the safety and tolerability of a switch to DOR/ISL compared with continued BIC/FTC/TAF, through Week 48. The primary hypotheses are that (1) DOR/ISL is non-inferior to continued BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48, with a margin of 4 percentage points used to define non-inferiority; and (2) DOR/ISL is superior to BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive DOR/ISL 100 mg/0.25 mg and Placebo to BIC/FTC/TAF once daily (QD) orally from day 1 to week 144. After week 144, eligible participants may continue on DOR/ISL and continue study treatment until week 240 or to when DOR/ISL becomes commercially accessible (whichever comes first).
Drug: DOR/ISL · Drug: Placebo to BIC/FTC/TAF
Participants will receive BIC/FTC/TAF 50 mg/200 mg/25 mg and Placebo to DOR/ISL once daily (QD) orally from day 1 to week 144. After week 144, eligible participants may switch to DOR/ISL and continue study treatment until week 240 or to when DOR/ISL becomes commercially accessible (whichever comes first).
Drug: BIC/FTC/TAF · Drug: Placebo to DOR/ISL
Drug pages: Doravirine · Islatravir
DOR/ISL 100 mg/0.25 mg oral tablets once daily
Also known as: MK-8591A, Doravirine/Islatravir
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
Also known as: Bictegravir/Emtricitabine/Tenofovir Alafenamide
0 mg oral tablets once daily
0 mg oral tablets once daily
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48
HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
Time frame: Week 48
Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE is reported.
Time frame: Up to Week 48
Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE is reported.
Time frame: Up to Week 48
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
Time frame: Week 48
Change From Baseline in Cluster of Differentiation 4-positive (CD4+) T-cell Count at Week 48
Plasma CD4+ T-Cell Count was measured in cells/mm\^3 for baseline and 48 weeks. Baseline measurements were defined as the Day 1 value of each participant. The change from baseline to Week 48 and corresponding 2-sided 95% confidence intervals were calculated based on cLDA models adjusted by treatment group, time, and the interaction of time-by-treatment group.
Time frame: Baseline at Day 1 and Week 48
Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48
Participants with clinically significant confirmed viremia \[2 consecutive occurences 4 weeks (+-1 week) apart of HIV-1 RNA ≥200 copies/mL at any time during the study\] or who discontinue study intervention for another reason with HIV-1 RNA ≥200 copies/mL at the time of discontinuation met the criteria for post-baseline resistance testing. Per protocol, participants with HIV-1 RNA ≥400 copies/mL or any participant for whom available genotypic or phenotypic data show evidence of resistance, irrespective of viral load were included in the resistance analysis subset. Plasma samples were collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and virus susceptibility to study intervention. The percentage of participants in the resistance analysis subset with treatment-emergent resistance-associated substitutions to the study intervention is presented.
Time frame: Up to Week 48
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96
Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 will be reported.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96
Percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 will be reported.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
Percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 will be reported.
Time frame: Week 96
Change From Baseline in CD4+ T-cell Count at Week 96
Mean change from baseline at Day 1 in CD4+ T-cell count at Week 96 will be reported.
Time frame: Baseline at Day 1 and Week 96
Number of Participants With Viral Drug Resistance Mutations at Week 96
Number of participants with evidence of viral drug resistance-associated substitutions at Week 96 will be reported.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144
Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144 will be reported.
Time frame: Week 144
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144
Percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 will be reported.
Time frame: Week 144
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144
Percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 will be reported.
Time frame: Week 144
Change From Baseline in CD4+ T-cell Count at Week 144
Mean change from baseline at Day 1 in CD4+ T-cell count at Week 144 will be reported.
Time frame: Baseline at Day 1 and Week 144
Number of Participants With Viral Drug Resistance Mutations at Week 144
Number of participants with evidence of viral drug resistance-associated substitutions at Week 144 will be reported.
Time frame: Week 144
Percentage of Participants Who Experience AEs Through Week 144
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to Week 144
Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 144
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to Week 144
| Milestone | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| Started | 343 | 171 |
| Treated | 342 | 171 |
| Completed | 10 | 6 |
| Not completed | 333 | 165 |
| Withdrew: Lost to follow-up | 7 | 0 |
| Withdrew: Randomized by mistake without study treatment | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 3 |
| Withdrew: Participant moved away from trial site | 0 | 1 |
| Withdrew: Status not recorded | 316 | 161 |
HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
| Percentage of Participants | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48 | 1.5 | 0.6 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE is reported.
| Percentage of Participants | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48 | 74.6 | 71.3 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE is reported.
| Percentage of Participants | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48 | 2.9 | 1.8 |
HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
| Percentage of Participants | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48 | 91.8 | 94.2 |
HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.
| Percentage of Participants | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48 | 91.5 | 94.2 |
Plasma CD4+ T-Cell Count was measured in cells/mm\^3 for baseline and 48 weeks. Baseline measurements were defined as the Day 1 value of each participant. The change from baseline to Week 48 and corresponding 2-sided 95% confidence intervals were calculated based on cLDA models adjusted by treatment group, time, and the interaction of time-by-treatment group.
| Cells/mm^3 | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| Change From Baseline in Cluster of Differentiation 4-positive (CD4+) T-cell Count at Week 48 | 30.40 (10.98 to 49.83) | 28.19 (-4.46 to 60.83) |
Participants with clinically significant confirmed viremia \[2 consecutive occurences 4 weeks (+-1 week) apart of HIV-1 RNA ≥200 copies/mL at any time during the study\] or who discontinue study intervention for another reason with HIV-1 RNA ≥200 copies/mL at the time of discontinuation met the criteria for post-baseline resistance testing. Per protocol, participants with HIV-1 RNA ≥400 copies/mL or any participant for whom available genotypic or phenotypic data show evidence of resistance, irrespective of viral load were included in the resistance analysis subset. Plasma samples were collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and virus susceptibility to study intervention. The percentage of participants in the resistance analysis subset with treatment-emergent resistance-associated substitutions to the study intervention is presented.
| Percentage of Participants | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48 | 0 | — |
Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 will be reported.
Results for this outcome have not been posted.
Percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 will be reported.
Results for this outcome have not been posted.
Percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 will be reported.
Results for this outcome have not been posted.
Mean change from baseline at Day 1 in CD4+ T-cell count at Week 96 will be reported.
Results for this outcome have not been posted.
Number of participants with evidence of viral drug resistance-associated substitutions at Week 96 will be reported.
Results for this outcome have not been posted.
Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144 will be reported.
Results for this outcome have not been posted.
Percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 will be reported.
Results for this outcome have not been posted.
Percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 will be reported.
Results for this outcome have not been posted.
Mean change from baseline at Day 1 in CD4+ T-cell count at Week 144 will be reported.
Results for this outcome have not been posted.
Number of participants with evidence of viral drug resistance-associated substitutions at Week 144 will be reported.
Results for this outcome have not been posted.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Results for this outcome have not been posted.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Results for this outcome have not been posted.
Collected over Up to 84 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DOR/ISL and Placebo to BIC/FTC/TAF | 0/343 (0%) | 15/342 (4.4%) | 94/342 (27.5%) |
| BIC/FTC/TAF and Placebo to DOR/ISL | 0/171 (0%) | 11/171 (6.4%) | 52/171 (30.4%) |
| Event | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| CellulitisInfections and infestations | 0/342 | 3/171 |
| AnaemiaBlood and lymphatic system disorders | 0/342 | 1/171 |
| Pancreatitis acuteGastrointestinal disorders | 2/342 | 0/171 |
| Anal abscessInfections and infestations | 0/342 | 1/171 |
| Herpes simplexInfections and infestations | 0/342 | 1/171 |
| OrchitisInfections and infestations | 0/342 | 1/171 |
| PneumoniaInfections and infestations | 1/342 | 1/171 |
| HaemarthrosisMusculoskeletal and connective tissue disorders | 0/342 | 1/171 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/342 | 1/171 |
| Generalised anxiety disorderPsychiatric disorders | 0/342 | 1/171 |
| Event | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL |
|---|---|---|
| NasopharyngitisInfections and infestations | 21/342 | 13/171 |
| FatigueGeneral disorders | 13/342 | 12/171 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 22/342 | 8/171 |
| COVID-19Infections and infestations | 21/342 | 9/171 |
| DiarrhoeaGastrointestinal disorders | 20/342 | 6/171 |
| InfluenzaInfections and infestations | 9/342 | 9/171 |
| DizzinessNervous system disorders | 11/342 | 9/171 |
| Age, Continuous(Years) | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL | Total |
|---|---|---|---|
| Mean | 47.6 ± 12.9 | 47.6 ± 13.1 | 47.6 ± 12.9 |
| Sex: Female, Male(Participants) | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL | Total |
|---|---|---|---|
| Female | 74 | 36 | 110 |
| Male | 269 | 135 | 404 |
| Ethnicity (NIH/OMB)(Participants) | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL | Total |
|---|---|---|---|
| Hispanic or Latino | 73 | 44 | 117 |
| Not Hispanic or Latino | 262 | 125 | 387 |
| Unknown or Not Reported | 8 | 2 | 10 |
| Race (NIH/OMB)(Participants) | DOR/ISL and Placebo to BIC/FTC/TAF | BIC/FTC/TAF and Placebo to DOR/ISL | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 20 | 10 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 112 | 47 | 159 |
| White | 206 | 106 | 312 |
| More than one race | 3 | 6 | 9 |
| Unknown or Not Reported | 2 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2023 to primary completion in Oct 2024, 20 months.
Results were first posted in Nov 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Islatravir